Equity Profile

GRFS

Grifols, S.A.

Health CareBiotechnology$4.9B

Feb28Mon

Pre-Earnings Brief

UpcomingQ3-2021After Close9:00 AM EST

Company Snapshot

Grifols, S.A. is a global healthcare company specializing in biotechnology, particularly in the production of plasma-derived medicines....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth will indicate whether the company is expanding its market share and successfully increasing sales.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

GRFS Q3-2021 Earnings Preview

Context

Company Snapshot

Grifols, S.A. is a global healthcare company specializing in biotechnology, particularly in the production of plasma-derived medicines. With a market cap of $5 billion, it plays a crucial role in treating various medical conditions, making it significant in the health care sector.

Earnings Scorecard·Last 7Q

EPS Beat Streak

EPS Beat Rate

14%

Avg EPS Surprise

-3.86%

Avg Stock Reaction

+1.41%

Last Quarter Recap

In the last quarter, Grifols reported an EPS of $0.24, which was below the expected $0.27, resulting in a 1.76% increase in stock price the following day. The company continues to face challenges in meeting analyst expectations.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Grifols' upcoming earnings report, especially given the company's historical performance. However, there is uncertainty due to recent misses in EPS estimates.

Bull Case

If Grifols can exceed EPS expectations and show strong revenue growth, it could signal a turnaround and boost investor confidence.

Bear Case

Conversely, if the company misses expectations again, it may raise concerns about its operational efficiency and future growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q3-2021, and how does it compare to analyst expectations?

The EPS figure will be critical in assessing the company's profitability and operational performance this quarter.

How has revenue changed compared to the previous quarter?

Understanding revenue trends will provide insight into the company's market position and growth trajectory.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Grifols' ability to rebound from previous misses, as the company has been investing in new technologies that could enhance efficiency.

Supporting Evidence

Options are pricing in a larger move than the historical average, indicating heightened expectations.

The company's recent investments in R&D could lead to better-than-expected results.

Key Risk

If the EPS comes in above $0.30, it could shift the market's perception of Grifols' growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is crucial as Grifols seeks to recover from previous misses and demonstrate its growth potential.

Bull Confirmed If

An EPS of $0.30 or higher would confirm the bull case and indicate improved operational efficiency.

Bear Confirmed If

An EPS below $0.20 would confirm the bear case and raise concerns about the company's ability to generate profit.

Pre-Earnings Positioning

Options Market

Implied Move

±6.05%

Historical Avg

±1.5%

Pricing rich

The options market is pricing in a significant move of about 6.05%, suggesting that traders anticipate volatility around the earnings announcement.

Options are pricing ±6.1% while GRFS has averaged ±1.5% over the last 7 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

35.6%

Calls (22K)P/C Ratio: 0.33Puts (600)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Grifols beats expectations, history suggests a potential stock increase of around 0.10%, confirming a positive outlook.

In-Line / Cautious

A cautious inline report may lead to minimal movement as investors await further commentary from management.

Miss

If the company misses expectations again, history suggests a potential decline of around 1.35%, raising concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or innovations in the pipeline.
2Details on cost management strategies and their impact on profitability.
3Insights into market demand for plasma-derived therapies.
4Management's outlook on future revenue growth and market conditions.
5Any commentary on competitive pressures in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Feb25

DHILReported

Diamond Hill Investment Group, Inc.

RecapView

Feb28

JLLReported

Company Snapshot

Grifols, S.A. is a global healthcare company specializing in biotechnology, particularly in the production of plasma-derived medicines....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth will indicate whether the company is expanding its market share and successfully increasing sales.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

GRFS Q3-2021 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 7Q

EPS Beat Streak

EPS Beat Rate

14%

Avg EPS Surprise

-3.86%

Avg Stock Reaction

+1.41%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Grifols can exceed EPS expectations and show strong revenue growth, it could signal a turnaround and boost investor confidence.

Bear Case

Conversely, if the company misses expectations again, it may raise concerns about its operational efficiency and future growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q3-2021, and how does it compare to analyst expectations?

The EPS figure will be critical in assessing the company's profitability and operational performance this quarter.

How has revenue changed compared to the previous quarter?

Understanding revenue trends will provide insight into the company's market position and growth trajectory.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Grifols' ability to rebound from previous misses, as the company has been investing in new technologies that could enhance efficiency.

Supporting Evidence

Options are pricing in a larger move than the historical average, indicating heightened expectations.

The company's recent investments in R&D could lead to better-than-expected results.

Key Risk

If the EPS comes in above $0.30, it could shift the market's perception of Grifols' growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is crucial as Grifols seeks to recover from previous misses and demonstrate its growth potential.

Bull Confirmed If

An EPS of $0.30 or higher would confirm the bull case and indicate improved operational efficiency.

Bear Confirmed If

An EPS below $0.20 would confirm the bear case and raise concerns about the company's ability to generate profit.

Pre-Earnings Positioning

Options Market

Implied Move

±6.05%

Historical Avg

±1.5%

Pricing rich

The options market is pricing in a significant move of about 6.05%, suggesting that traders anticipate volatility around the earnings announcement.

Options are pricing ±6.1% while GRFS has averaged ±1.5% over the last 7 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

35.6%

Calls (22K)P/C Ratio: 0.33Puts (600)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Grifols beats expectations, history suggests a potential stock increase of around 0.10%, confirming a positive outlook.

In-Line / Cautious

A cautious inline report may lead to minimal movement as investors await further commentary from management.

Miss

If the company misses expectations again, history suggests a potential decline of around 1.35%, raising concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or innovations in the pipeline.
2Details on cost management strategies and their impact on profitability.
3Insights into market demand for plasma-derived therapies.
4Management's outlook on future revenue growth and market conditions.
5Any commentary on competitive pressures in the biotechnology sector.